Targeted Tozaride Drug Therapy for Small Cell Lung and neuroendocrine Cancer
SOMERVILLE, Mass.— June 2, 2017 — Andarix Pharmaceuticals, a clinical stage
company, announced today the publication of results of a phase1/2 clinical study in lung
and neuroendocrine cancer patients. The abstract will be presented at the annual
American Society of Clinical Oncology (ASCO) conference in Chicago, IL June 2-6 2017.
Abstract e20016: Targeted radiopeptide therapy Re188-P2045 to treat neuroendocrine
The complete text of the abstract is available online at abstracts.asco.org.
Tozaride is a novel, best-in- class therapy for lung and other cancers based on the radio-
labeled somatostatin peptide Tozaride. Early clinical studies of Tozaride demonstrated
that it is well tolerated and may produce prolonged stable disease and improved overall
survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted
radiotherapy represents a new treatment paradigm which is expected to yield significant
clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer
(NSCLC) patients, and which will provide another treatment option for patients who are
not eligible for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company developing targeted imaging and
therapies for lung, neuroendocrine, and other cancers based on a proprietary
somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin
receptors are highly up-regulated on several solid tumors, particularly lung cancers.
Lung cancer is the leading cause of cancer mortality in the United States for both men
and women. In 2013, there were an estimated 225,470 new diagnoses of non-small cell
lung cancer (NSCLC) with 42,000 small cell lung cancer patients. To learn more about
Andarix, please visit www.andarix.com.